Praxis Precision Medicines
Praxis Precision Medicines Inc is an American clinical-stage biopharmaceutical company focused on translating genetic insights into the discovery and development of novel therapies for central nervous system disorders characterized by neuronal hyperexcitability. The company utilizes its proprietary computational and translational research platforms to develop small-molecule therapeutic candidates targeting severe neurological conditions, including epilepsy, essential tremor, and developmental encephalopathies. Its core business activities encompass preclinical neuropharmacology, genetic biomarker research, clinical trial advancement, and biotechnology drug design. As a clinical-stage biotechnology firm, the company generates minimal commercial revenue and finances its drug development pipeline through public equity offerings and pharmaceutical collaborations. Praxis Precision Medicines holds an innovative position in precision neurology and CNS drug discovery. The company is headquartered in Boston, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Praxis Precision Medicines.
- Legal name
- Praxis Precision Medicines Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
Funds holding Praxis Precision Medicines
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 3.98 % (largest positions only, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.88 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 0.79 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.5 % (full portfolio disclosed, October 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.39 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.07 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.06 % (full portfolio disclosed, September 2026)